Adam Kadlec
Vorstandsvorsitzender bei Rivermark Medical, Inc.
Profil
Adam Kadlec is currently the President, Chief Executive Officer & Director at Rivermark Medical, Inc. and an Advisor at Golden Angels Investors LLC since 2018.
He completed his undergraduate and graduate degrees at the University of Wisconsin.
Aktive Positionen von Adam Kadlec
| Unternehmen | Position | Beginn |
|---|---|---|
Golden Angels Investors LLC
 Golden Angels Investors LLC Investment ManagersFinance Golden Angels Investors LLC (Golden Angels Investors) is a venture capital firm founded in 2002 by Timothy J Keane. The firm is headquartered in Brookfield, Wisconsin. | Berater | 01.04.2018 |
Rivermark Medical, Inc.
 Rivermark Medical, Inc. Medical SpecialtiesHealth Technology The American company was founded by a practicing urologist with the aim of developing the preferred first-line device therapy for benign prostatic hyperplasia. The company's flagship product, the Flostent system, enables physicians to treat patients safely and efficiently, with minimal discomfort and reduced complications. Rivermark Medical plans to bring the Flostent system to market as their first product. The CEO of the company is Adam Kadlec. | Vorstandsvorsitzender | 01.08.2021 |
Ausbildung von Adam Kadlec
| University of Wisconsin | Graduate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Private Unternehmen | 2 |
|---|---|
Golden Angels Investors LLC
Golden Angels Investors LLC Investment ManagersFinance Golden Angels Investors LLC (Golden Angels Investors) is a venture capital firm founded in 2002 by Timothy J Keane. The firm is headquartered in Brookfield, Wisconsin. | Finance |
Rivermark Medical, Inc.
Rivermark Medical, Inc. Medical SpecialtiesHealth Technology The American company was founded by a practicing urologist with the aim of developing the preferred first-line device therapy for benign prostatic hyperplasia. The company's flagship product, the Flostent system, enables physicians to treat patients safely and efficiently, with minimal discomfort and reduced complications. Rivermark Medical plans to bring the Flostent system to market as their first product. The CEO of the company is Adam Kadlec. | Health Technology |
